Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Certara and Critical Path Institute to develop lung model for TB drug testing
October 2013
SHARING OPTIONS:

ST. LOUIS—Certara and the Critical Path Institute have announced that they will be partnering in an effort to develop a physiologically based pharmacokinetic model of the human lung. The model will be developed to work in conjunction with Certara's Simcyp Population-based Simulator and will be used to predict how drugs will react in the lungs and the possible impact of disease progression on drugs during different stages of tuberculosis infection. The lung model's development is being supported by the Critical Path to TB Drug Regimens Initiative. No financial details were released.
 
"This lung simulation tool will allow pharmaceutical companies to simulate a wide range of variables in terms of drug dose, disease state and concomitant medications for a much more efficient clinical trial design process," said Dr. Daniel Weiner, senior vice president and general manager at Certara.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.